Weight-loss miracle drugs may inhibit cancer progression; Novo Nordisk and Eli Lilly receive major positive news
```
The world's best-selling weight loss and diabetes medications may be on the verge of another major breakthrough.
Four new studies show that GLP-1 drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro are associated with better treatment outcomes in cancer patients, potentially further expanding the market prospects for these drugs—which already have tens of millions of users—and providing new growth drivers for the world’s two highest-valued pharmaceutical companies.
The studies will be published later this month at the annual meeting of the American Society of Clinical Oncology (ASCO), covering data from more than hundreds of thousands of patients.
The largest study among them comes from Cleveland Clinic’s Cancer Institute, tracking over 10,000 early-stage cancer patients. Results show that GLP-1 users had a significantly lower risk of cancer progression compared to the control group—the progression rate for lung cancer patients was reduced by about half, and for breast cancer patients, the rate dropped from 20% to 10%.
Other studies show that the five-year survival rate for breast cancer patients using GLP-1 drugs exceeds 95%, compared to 89.5% for non-users.
If the anti-cancer benefits are ultimately confirmed, it will further consolidate Novo Nordisk and Eli Lilly’s industry positions. GLP-1 drugs are already approved for reducing the risk of heart attack and stroke, and are being tested for efficacy against sleep apnea and addictive behaviors. Anti-cancer benefits would further expand the medical value boundaries of these drugs and could reshape their pricing and reimbursement logic.
However, researchers explicitly note that current evidence only shows correlation, not causation. All four studies are retrospective observational studies, relying on insurance claim records and medical databases, and need randomized controlled trials for confirmation. Currently, neither Novo Nordisk nor Eli Lilly have launched targeted clinical studies for the anti-cancer effects of their GLP-1 drugs.
Significant Decline in Progression Rates across Multiple Cancer Types, Consistent Data Signals
Cleveland Clinic’s study compared over 10,000 early-stage cancer patients who began GLP-1 medication after diagnosis with patients using other diabetes drugs, showing that GLP-1 users had lower risk of cancer spread.
The specific data are quite noteworthy: among lung cancer patients, the progression to advanced stage in the GLP-1 group was about 10%, versus 22% in the control group—a reduction of about 50%. For breast cancer patients, progression rates were 10% versus 20%. Statistically significant reductions were also seen in colorectal and liver cancers.
"Given that millions of Americans are using GLP-1 drugs, we clearly need to understand their potential anti-tumor effects," said Dr. Mark Orland, a Cleveland Clinic resident who will present the study at the ASCO annual meeting.
Dr. Jennifer Ligibel, a breast oncologist at Dana-Farber Cancer Institute who was not involved in any of the studies, said, "In several types of cancer, people using these drugs seem to have lower recurrence risk, and this finding is indeed striking."
Breast Cancer Data: Improved Incidence and Survival Rates
The other two studies focus specifically on breast cancer, examining the potential role of GLP-1 drugs in both incidence and survival.
The University of Texas MD Anderson Cancer Center analyzed over 137,000 breast cancer patients and found that GLP-1 users had a five-year survival rate exceeding 95%, compared to 89.5% for non-users.
University of Pennsylvania’s study included nearly 95,000 women who underwent breast imaging, and found that those who had used GLP-1 drugs had about 25% lower risk of being diagnosed with breast cancer, a difference that persisted even after controlling for age, weight, and other risk factors.
Dr. Jasmine Sukumar, a breast oncologist at MD Anderson and participant in the survival rate study, said: "We observed signals in multiple databases, and this really deserves attention, because these studies are designed very differently."
Debate about Mechanisms: Metabolic Improvement or Direct Tumor Targeting?
The scientific community currently has no consensus on why GLP-1 drugs may produce anti-cancer effects, with two main hypotheses.
The first is that GLP-1 drugs indirectly reduce cancer risk by promoting weight loss and improving metabolic health, and both weight control and metabolic health are independently associated with lower cancer incidence.
The second is that GLP-1—the hormone mimicked by these drugs—receptors exist on the surface of some tumor cells, suggesting the drugs may directly affect cancer’s biological processes. Whichever mechanism is ultimately proven, it would have significant long-term medical and commercial implications for these drugs.
Limitations of Observational Studies Cannot Be Ignored, Confirmation Still Needs Randomized Trials
Despite consistent data signals, researchers remain cautious about the limitations of current studies.
All four studies rely on retrospective insurance claim records and medical databases, which carry inherent bias risks: patients prescribed GLP-1 drugs often have better access to medical resources and more stable follow-up records. These factors themselves may independently improve treatment outcomes, making it difficult to separate their effects from those of the drugs.
To confirm whether GLP-1 drugs themselves drive these benefits, randomized controlled trials—with rigorous control of income level, baseline health status, and medical resource differences—are needed.
Currently, neither Novo Nordisk nor Eli Lilly have initiated research specifically for cancer indications. Nevertheless, Dr. Jaroslaw Maciejewski, Vice Chair of Cleveland Clinic Cancer Institute and lead author of the related research, stated that the consistency of data across hundreds of thousands of patients “is hard to ignore.”
Risk Warning and DisclaimerThe market has risks, investment requires caution. This article does not constitute individual investment advice, nor does it take into account the special investment targets, financial situations, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Invest accordingly at your own risk. ```